Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cogent BiosciencesCOGT +2.95%30 Cash Ratio is 14.94 as of Mar. 2026, which is 102% above its 10-year median of 7.40. GuruFocus rates COGT with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 1,385 Biotechnology companies, Cogent Biosciences ranks better than 88.3% on this metric.
Cogent Biosciences has a Cash Ratio of 14.94. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Cogent Biosciences's Cash Ratio or its related term are showing as below:
COGT'
s Cash Ratio Range Over the Past 10 Years
Min: 1.41 Med: 7.4 Max: 28
Current: 14.94
During the past 11 years, Cogent Biosciences's highest Cash Ratio was 28.00. The lowest was 1.41. And the median was 7.40.
COGT's Cash Ratio is ranked better than 88.3% of 1385
companies
in the Biotechnology industry
Industry Median: 2.95
vs COGT: 14.94
Cogent Biosciences (NAS:COGT) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Cogent Biosciences Cash Ratio Related Terms
Cogent Biosciences Cash Ratio Historical Data
* Premium members only.
The historical data trend for Cogent Biosciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cogent Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogent Biosciences (COGT) has a Cash Ratio of 14.94 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cogent Biosciences and its competitors. This is 102% above median its historical median of 7.40. Over the past decade, Cogent Biosciences' Cash Ratio has ranged from 1.41 to 28.00. According to the industry distribution chart, Cogent Biosciences ranks #162 out of 1385 companies in the Biotechnology industry, placing it in the top 11.7%.
Is Cogent Biosciences' Cash Ratio too high?
Cogent Biosciences' current Cash Ratio of 14.94 is 102% above median its 10-year median of 7.40. Over the past 10 years, this metric has ranged from a low of 1.41 to a high of 28.00. The Biotechnology industry median Cash Ratio is 2.95. Cogent Biosciences' value of 14.94 is 406.4% above this industry median. Based on the distribution chart, Cogent Biosciences ranks #162 out of 1385 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cogent Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' Cash Ratio compare to SRRK and CGON?
According to the Biotechnology industry distribution chart, Cogent Biosciences ranks #162 out of 1385 companies for Cash Ratio. This places Cogent Biosciences in the top 12% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.95. Cogent Biosciences' value of 14.94 is 406.4% above this benchmark. Historically, Cogent Biosciences' own Cash Ratio has ranged from 1.41 to 28.00 over the past decade. While the company's 10-year median is 7.40 vs. the industry median of 2.95, Cogent Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.95, based on 1,385 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cogent Biosciences's current Cash Ratio of 14.94 is 406.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cogent Biosciences and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cogent Biosciences's current Cash Ratio is 14.94, which is 102% above median its own 10-year median of 7.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current Cash Ratio of 14.94. The current Cash Ratio is 14.94, which is 102% above median its 10-year median of 7.40 and 406.4% above the Biotechnology industry median of 2.95. Cogent Biosciences' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current Cash Ratio is 14.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
30GF Score
Get the complete analysis for COGT
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COGT has been successfully added to your 
